GGrantIndex
Sort

82,697 grants matching vaccine development

DEVELOPMENT OF TUBERCULOSIS VACCINE FORMULATIONS

$2,748,153
Chris Fox · Access To Advanced Health Institute · N01 · FY2017 · AI

Pre-clinical Vaccine Development for Respiratory Viruses

$2,748,001
John Mascola · National Institute Of Allergy And Infectious Diseases · ZIC · FY2020 · AI

NCI-Frederick Support and Technical Services

$2,747,915
John Niederhuber · Office Of The Director, Nci · ZIC · FY2009 · CA

Clinical Trials of Parainfluenza and Respiratory Syncytial Virus Vaccines

$2,747,716
Peter Leon Collins · National Institute Of Allergy And Infectious Diseases · ZIA · FY2011 · AI

Indiana University Melvin and Bren Simon Cancer Center Support Grant

$2,746,580
Kelvin P Lee · Indiana University Indianapolis · P30 · FY2021 · CA

Indiana University Melvin and Bren Simon Cancer Center Support Grant

$2,746,580
Kelvin P Lee · Indiana University Indianapolis · P30 · FY2020 · CA

Indiana University Melvin and Bren Simon Cancer Center Support Grant

$2,746,580
Kelvin P Lee · Indiana University Indianapolis · P30 · FY2022 · CA

Indiana University Melvin and Bren Simon Cancer Center Support Grant

$2,746,580
Kelvin P Lee · Indiana University Indianapolis · P30 · FY2023 · CA

Bone Marrow Grafting and Cellular Therapy for Leukemia and Lymphoma

$2,745,884
Robert S Negrin · Stanford University · P01 · FY2019 · CA

The Role of Inflammasome Signaling in Tauopathies

$2,745,818
Kiran Bhaskar · University Of New Mexico Health Scis Ctr · RF1 · FY2020 · NS

Immune Responses to Malaria and HIV Infection and Immunization

$2,742,800
Kenneth D Stuart · Seattle Biomedical Research Institute · U19 · FY2017 · AI

Immunologic evaluation of HIV-1 HVTN experimental medicine trials HVTN 307, HVTN 309 and HVTN312

$2,741,630
Barton F Haynes · Duke University · UM1 · FY2024 · AI

Antigen-specific T-cell Activation, Application to Vaccines for Cancer and AIDS

$2,741,261
Jay A Berzofsky · Division Of Clinical Sciences - Nci · ZIA · FY2009 · CA

HIV-1 VACCINE CANDIDATES DELIVERED BY VSV VECTORS

$2,740,852
John Eldridge · Profectus Biosciences, Inc. · N01 · FY2010 · AI

NIDA Clinical Trials Network: Greater New York Node

$2,740,413
John P Rotrosen · New York University School Of Medicine · UG1 · FY2019 · DA

Immune Modulation After Allogeneic HCT

$2,740,234
Robert Jon Soiffer · Dana-Farber Cancer Inst · P01 · FY2020 · CA

Development of Technologies to Facilitate the Use of and Response to Vaccines

$2,739,889
Laurence Lemiale · Emergent Product Development Gaithersbur · N01 · FY2020 · AI

Immune Modulation After Allogeneic HCT

$2,739,426
Robert Jon Soiffer · Dana-Farber Cancer Inst · P01 · FY2021 · CA

Bone Marrow Grafting and Cellular Therapy for Leukemia and Lymphoma

$2,739,423
Robert S Negrin · Stanford University · P01 · FY2020 · CA

WEILL CORNELL PROGRAM OF EXCELLENCE IN GENE THERAPY

$2,739,199
Weill Medical College Of Cornell Univ · U01 · FY2001 · HL

WEILL CORNELL PROGRAM OF EXCELLENCE IN GENE THERAPY

$2,739,199
Weill Medical College Of Cornell Univ · U01 · FY2004 · HL

Task A25: Development of Rat Animal Model

$2,738,715
Rick Lyons · University Of New Mexico Health Scis Ctr · N01 · FY2011 · AI

Emerging Infectious Diseases Research Centers Coordination Center (EIDRC CC)

$2,738,672
Gregory D Sempowski · Research Triangle Institute · U01 · FY2024 · AI

Spore in Head and Neck Cancer

$2,737,829
David Sidransky · Johns Hopkins University · P50 · FY2016 · DE

UCLA AIDS Prevention and Treatment Clinical Trials Unit

$2,737,442
Judith S. Currier · University Of California Los Angeles · UM1 · FY2014 · AI